TNX-102 SL Emerging

“TNX-102 SL Market Size, Forecast, and Emerging Insight – 2032” report provides comprehensive insights about TNX-102 SL for chronic pain in the seven major markets. A detailed picture of the TNX-102 SL for chronic pain in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 is provided in this report along with a detailed description of the TNX-102 SL for chronic pain. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the TNX-102 SL market forecast analysis for chronic pain in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in chronic pain.

Drug Summary

TNX-102 SL, a proprietary sublingual tablet formulation containing 2.8 mg of cyclobenzaprine HCl, is taken daily at bedtime to manage fibromyalgia. It is a small, rapidly-disintegrating product candidate which provides rapid transmucosal absorption and reduced production of a long half-life active metabolite, norcyclobenzaprine, due to bypass of first-pass hepatic metabolism. The unique patented formulation has been designed to optimize the delivery and absorption of cyclobenzaprine for the therapeutic benefit of improving sleep quality while minimizing the potential residual effects of oral formulations of cyclobenzaprine. TNX-102 SL is a centrally-acting analgesic that helps relieve pain by improving sleep. It is in mid-Phase III development for the management of fibromyalgia.

RELIEF, the first Phase III study of TNX-102 SL in patients with fibromyalgia completed in October 2020. In December 2020, Tonix Pharmaceuticals reported positive results from the study (primary endpoint, p = 0.010).

In March 2022, Tonix Pharmaceuticals announced that TNX-102 SL did not achieve statistical significance on the primary endpoint of reducing fibromyalgia (FM) daily pain at Week 14 compared to placebo (p = 0.115) in the Phase III RALLY study. RALLY had an unexpected increase in study participant adverse event-related discontinuations in both drug and placebo groups.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the TNX-102 SL description, mechanism of action, dosage and administration, research and development activities in chronic pain.
• Elaborated details on TNX-102 SL regulatory milestones and other development activities have been provided in this report.
• The report also highlights the TNX-102 SL research and development activities in chronic pain across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around TNX-102 SL.
• The report contains forecasted sales of for chronic pain till 2032.
• Comprehensive coverage of the late-stage emerging therapies for chronic pain.
• The report also features the SWOT analysis with analyst views for TNX-102 SL in chronic pain.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

TNX-102 SL Analytical Perspective by DelveInsight

In-depth TNX-102 SL Market Assessment

This report provides a detailed market assessment of TNX-102 SL for chronic pain in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2025 to 2032.

TNX-102 SL Clinical Assessment

The report provides the clinical trials information of TNX-102 SL for chronic pain covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights 

• In the coming years, the market scenario for chronic pain is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.  
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence TNX-102 SL dominance.
• Other emerging products for chronic pain are expected to give tough market competition to TNX-102 SL and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of TNX-102 SL in chronic pain.
• Our in-depth analysis of the forecasted sales data of TNX-102 SL from 2025 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the TNX-102 SL in chronic pain.

Key Questions

• What is the product type, route of administration and mechanism of action of TNX-102 SL?
• What is the clinical trial status of the study related to TNX-102 SL in chronic pain and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the TNX-102 SL development?
• What are the key designations that have been granted to TNX-102 SL for chronic pain?
• What is the forecasted market scenario of TNX-102 SL for chronic pain?
• What are the forecasted sales of TNX-102 SL in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan? 
• What are the other emerging products available and how are these giving competition to TNX-102 SL for chronic pain?
• Which are the late-stage emerging therapies under development for the treatment of chronic pain?